Alzheimer s & Dementia Translational Research & Clinical Interventions · 2019 · 13 citations · 34 references
PharmacyNeurosciencePharmacologyDrug DeliveryMolecular NeuroscienceNeurodegenerationBlood-brain Barrier DeliveryBlood-brain Barrier PenetrationIron TransportNeurodegenerative DiseasesNeuroprotectionPeptide DeliveryAlzheimer’s Disease Barrier DysfunctionBlood-brain Barrier Iron TransportBlood-brain Barrier Peptide TransportCarrier-mediated Transport Across The Blood-brain BarrierLipoprotein Receptor TargetingNeuronal NecrosisPeptide-mediated Brain TargetingTargeted Delivery Across The Blood-brain Barrier
INTRODUCTION: Iron accumulates in the brain during aging, which catalyzes radical formation, causing neuronal impairment, and is thus considered a pathogenic factor in Alzheimer's disease (AD). To scavenge excess iron-catalyzed radicals and thereby protect the brain and decrease the incidence of AD, we synthesized a soluble pro-iron 5-YHEDA peptide. However, the blood-brain barrier (BBB) blocks large drug molecules from entering the brain and thus strongly reduces their therapeutic effects. However, alternative receptor- or transporter-mediated approaches are possible. METHODS: A low-density lipoprotein receptor (LDLR)-binding segment of Apolipoprotein B-100 was linked to the 5-YHEDA peptide (bs-5-YHEDA) and intracardially injected into senescent (SN) mice that displayed symptoms of cognitive impairment similar to those of people with AD. RESULTS: We successfully delivered 5-YHEDA across the BBB into the brains of the SN mice via vascular epithelium LDLR-mediated endocytosis. The data showed that excess brain iron and radical-induced neuronal necrosis were reduced after the bs-5-YHEDA treatment, together with cognitive amelioration in the SN mouse, and that the senescence-associated ferritin and transferrin increase, anemia and inflammation reversed without kidney or liver injury. DISCUSSION: bs-5-YHEDA may be a mild and safe iron remover that can cross the BBB and enter the brain to relieve excessive iron- and radical-induced cognitive disorders.
34
Warren J. Strittmatter, Karl H. Weisgraber, Daoyuan Huang et al. · Proceedings of the National Academy of Sciences · 1993 · 1.4K citations
Iron-Chelating Therapy and the Treatment of Thalassemia
Nancy F. Olivieri, Gary M. Brittenham · Blood · 1997 · 1.1K citations · Full text
Transferrin receptor on endothelium of brain capillaries
Wilfred A. Jefferies, Malcolm R. Brandon, Simon V. Hunt et al. · Nature · 1984 · 1.1K citations
Characterization of Copper Interactions with Alzheimer Amyloid β Peptides
Craig Atwood, Richard C. Scarpa, Xudong Huang et al. · Journal of Neurochemistry · 2000 · 638 citations
Structure of apolipoprotein B-100 in low density lipoproteins
Jere P. Segrest, Martin K. Jones, Hans De Loof et al. · Journal of Lipid Research · 2001 · 514 citations · Full text